Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna
Kristina A. Tendl(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Florian Fitzal, Elisabeth Bergen(Medical University of Vienna), Margaretha Rudas(Comprehensive Cancer Center Vienna), Laura Monschein(Vienna General Hospital), Ruth Exner(Comprehensive Cancer Center Vienna), Leonhard Müllauer(Hochschule Campus Wien), Michael Seifert(Zimmer Biomet (Germany)), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 1
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540